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ABSTRACT 1 
Stromal remodeling, in particular fibroblast-to-myofibroblast differentiation, is a hallmark of benign 2 
prostatic hyperplasia (BPH) and solid tumors, including prostate cancer (PCa). Increased local 3 
production of TGFbeta1 is considered the inducing stimulus. Given that stromal remodeling actively 4 
promotes BPH/PCa development, there is considerable interest in developing stromal-targeted 5 
therapies. Microarray and quantitative PCR analysis of primary human prostatic stromal cells (PrSCs) 6 
induced to undergo fibroblast-to-myofibroblast differentiation with TGFbeta1 revealed up-regulation 7 
of the ROS producer NADPH oxidase 4 (NOX4) and down-regulation of the selenium-containing 8 
ROS scavenging enzymes Glutathione peroxidase 3 (GPX3), Thioredoxin reductase 1 (TXNRD1) and 9 
the selenium transporter Selenoprotein P plasma 1 (SEPP1). Consistently, NOX4 expression 10 
correlated specifically with the myofibroblast phenotype in vivo and loss of SEPP1 was observed in 11 
tumor-associated stroma of human PCa biopsies. Using lentiviral NOX4 shRNA-mediated 12 
knockdown, pharmacological inhibitors, antioxidants and selenium, we demonstrate that TGFbeta1 13 
induction of NOX4-derived ROS is required for TGF1-mediated phosphorylation of JNK, which in 14 
turn is essential for subsequent downstream cytoskeletal remodeling. Significantly, selenium 15 
supplementation inhibited differentiation by increasing ROS scavenging selenoenzyme biosynthesis 16 
since GPX3 and TXNRD1 expression and TXNRD1 enzyme activity were restored. Consistently, 17 
selenium depleted ROS levels downstream of NOX4 induction. Collectively, this work demonstrates 18 
that dysregulated redox homeostasis driven by elevated NOX4-derived ROS signaling underlies 19 
fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Further, these data indicate 20 
the potential clinical value of selenium and/or NOX4 inhibitors in preventing the functional 21 
pathogenic changes of stromal cells in BPH and PCa. 22 
 3
INTRODUCTION 1 
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two of the most common diseases 2 
affecting aging males (1-3). Although distinct pathologies, BPH and PCa are both associated with 3 
changes in the stromal microenvironment that actively promote disease development (4, 5). In 4 
particular, the BPH and PCa-adjacent stroma (the latter also termed reactive stroma) are characterized 5 
by increased extracellular matrix (ECM) deposition, capillary density and differentiation of fibroblast 6 
into myofibroblasts, whose mitogenic secretome promotes proliferation, angiogenesis and 7 
tumorigenesis (6-9). Initial treatments for BPH and local-confined PCa target androgen 8 
signaling/metabolism resulting in apoptosis of androgen-dependent cells and reduced prostate volume 9 
(10, 11). However, neither approach specifically addresses the stromal component of disease. 10 
Understanding the mechanisms underlying stromal remodeling in particular fibroblast-to-11 
myofibroblast differentiation may facilitate the development of preventive or more effective treatment 12 
strategies. 13 
Elevated production of the cytokine TGFbeta1 (TGF1) is observed in BPH and pre-tumorigenic 14 
prostatic lesions with tissue and circulating levels positively correlating with disease risk and more 15 
rapid PCa progression (12, 13). We and others demonstrated that TGF1 induces fibroblast-to-16 
myofibroblast differentiation and stromal remodeling both in vitro and in vivo (14-16). TGF1 is thus 17 
considered a key inducer of pathogenic stromal reorganization, however its downstream molecular 18 
effectors and hence potential therapeutic targets remain unknown. 19 
Excessive levels of reactive oxygen species (ROS) are associated with the pathology of many human 20 
diseases. By contrast, various cellular stimuli (e.g. growth factors, cytokines and hormones) induce the 21 
regulated production of low levels of ROS. In such cellular contexts, ROS act as signaling messengers 22 
regulating diverse physiological processes via reversible oxidative modification of lipids, DNA and 23 
specific cysteine residues of susceptible proteins (e.g. transcription factors, protein tyrosine kinases,  24 
and protein tyrosine phosphatases) resulting in altered activity and function (17). 25 
The NADPH oxidase (NOX) family is a major source of intracellular ROS (18). NOX enzymes 26 
catalyze the reduction of oxygen using cytosolic NADPH as an electron donor generating superoxide, 27 
which may undergo subsequent dismutation to hydrogen peroxide. Of the seven NOX enzymes in 28 
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humans, NOX1 and NOX2 play a role in host defense whereas ROS produced by other NOX enzymes 1 
act primarily as signaling molecules (19). Dysregulated NOX4 expression is implicated in 2 
differentiation associated with cardiac fibrosis and idiopathic lung pulmonary fibrosis (20, 21). 3 
However, the molecular mechanism by which NOX4-derived ROS directed differentiation was not 4 
identified. 5 
The potentially damaging effects of ROS are limited by antioxidant systems, such as glutathione 6 
peroxidases (GPXs) and thioredoxin reductases (TXNRDs). An integral component of GPX and 7 
TXNRD enzymes is the essential trace element selenium (Se), which is incorporated as seleno-8 
cysteine (Se-Cys) at their active site (22). The expression and biosynthesis of such selenoproteins is 9 
determined by Se status in a strict hierarchical manner (23, 24). Due to its high levels in plasma and an 10 
unusually high Se-Cys content, Selenoprotein P plasma 1 (SEPP1) is primarily thought to function as 11 
a Se transporter (25). 12 
We demonstrate that TGF1-mediated fibroblast-to-myofibroblast differentiation of primary human 13 
prostatic stromal cells (PrSCs) is driven via induction of NOX4/ROS signaling. NOX4/ROS induce 14 
the phosphorylation of JNK, which subsequently activates the downstream transcriptional program of 15 
differentiation. Elevated ROS signaling is supported by the concomitant down-regulation of selenium-16 
containing ROS scavenging enzymes and the selenium transporter SEPP1. Selenium supplementation 17 
restored expression of selenium-containing ROS scavengers, increased TXNRD1 activity, depleted 18 
NOX4-derived ROS levels and attenuated differentiation. The potential clinical value of selenium 19 
and/or NOX4 inhibitors in preventing the transformation of stromal cells in BPH and PCa is indicated. 20 
 5
RESULTS 1 
Dysregulation of redox-regulators during prostatic fibroblast differentiation 2 
To investigate the molecular changes during BPH/PCa-associated fibroblast-to-myofibroblast 3 
differentiation the expression profiles of TGF1-induced differentiated and non-differentiated PrSCs 4 
were analyzed by Affymetrix microarray. 1611 genes were identified with at least 2.5 fold change in 5 
their expression levels. Consistent with previous reports a significant proportion of regulated genes 6 
encoded ECM components or enzymes involved in ECM remodeling (9, 15) (Supplemental Table 1). 7 
One of the most strongly induced genes was NOX4 (436.6 ± 20.8 fold). Of the other known NOX and 8 
associated genes, the regulatory phox subunit p67phox (NCF2) was also significantly up-regulated. In 9 
addition, several genes encoding proteins with ROS scavenging function were significantly down-10 
regulated, including Selenoprotein P plasma 1 (SEPP1), Glutathione peroxidase 3 (GPX3), 11 
Thioredoxin (TXN) and Thioredoxin reductase 1 (TXNRD1) (supplemental Table 1). These data were 12 
verified by quantitative PCR (qPCR; Fig. 1). The superior sensitivity of qPCR over microarray for the 13 
detection of low abundance transcripts revealed that despite their very low basal expression (ct value 14 
<35) NOX1 and NOX5 were marginally but significantly down-regulated during TGF1-induced 15 
differentiation (-2.8 ± 0.4 and -2.9 ± 0.4 fold, respectively, p-value = 0.0005). NOX2 or NOX3 were 16 
not detectably expressed in PrSCs (not shown). These data suggest that TGF1-induced differentiation 17 
of PrSCs is associated with a NOX4-driven pro-oxidant shift in redox homeostasis. 18 
 19 
NOX4 expression correlates with the myofibroblast phenotype in vivo 20 
NOX4 expression was verified by qPCR in non-tumor containing small prostate samples derived from 21 
radical prostatectomies (n = 13, Fig. 1B) and compared to the expression of a panel of epithelial-, 22 
stromal- and myofibroblast-specific markers (Fig. 1C). NOX4 exhibited no correlation with 8 23 
epithelial markers but weakly correlated with 6 stromal markers (R2 = 0.21) and more strongly with 5 24 
different myofibroblast markers (R2 = 0.76). Thus, consistent with our observation from in vitro 25 
induced fibroblast-to-myofibroblast differentiation of PrSCs, NOX4 mRNA levels specifically 26 
correlate with the myofibroblast phenotype in vivo. 27 
 28 
 6
Specific loss of SEPP1 in tumor-associated stroma of human prostate biopsies 1 
Down-regulation of the Se transporter SEPP1 during differentiation (-14.2 ± 2.8 fold by qPCR; Fig. 2 
1A) was confirmed at the protein level in cell lysates by Western blotting (-2.4 ± 0.2 fold; Fig. 1D). 3 
Moreover, secreted SEPP1 could be detected in the culture media from prostatic fibroblasts but not in 4 
the supernatants from TGF1-induced differentiated PrSCs (Fig. 1D). 5 
To determine whether loss of SEPP1 is associated with pathogenic stromal remodeling in vivo, 6 
prostate biopsies from normal/BPH and PCa patients were stained for SEPP1 by 7 
immunohistochemistry (Fig. 1E). Specificity of the SEPP1 signal was verified by pre-blocking with a 8 
peptide corresponding to residues 244-258 of human SEPP1 against which the antibody was raised 9 
(Fig. 1E) (26). In normal prostate (n = 12), strong SEPP1 cytoplasmic staining was observed in basal 10 
and luminal epithelial cells and smooth muscle cells (SMCs). Periglandular stromal cells (fibroblasts, 11 
perivascular and endothelial cells) were moderately stained (Fig. 1E). However, in biopsies of PCa 12 
patients (Gleason 7, n = 8) SEPP1 immunoreactivity was specifically lost in the periglandular tumor-13 
associated (reactive) stroma whereas adjacent bundles of smooth muscle and tumor cells stained 14 
positive (Fig. 1E). Thus, consistent with the reduction of SEPP1 in differentiated PrSCs, the 15 
remodeled prostatic stroma in PCa exhibits specific loss of stromal SEPP1. 16 
 17 
Elevated ROS production precedes fibroblast differentiation 18 
To determine the functional significance of TGF1-induced NOX4 expression and suppression of 19 
ROS scavengers, ROS production was measured in PrSCs via luminol-based chemiluminescence and 20 
using the intracellular probes dihydroethidium (DHE) and 5-(and-6)-chloromethyl-2',7'-21 
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Fig. 2A-B and data not shown). 22 
In comparison to basic fibroblast growth factor (bFGF) treated control cells, TGF1-differentiated 23 
PrSCs produced significantly elevated ROS levels (2.6 fold ±0.1 by H2DCFDA and 10.2 fold ±1.7 by 24 
luminol), which could be rapidly ablated with the NOX inhibitor diphenylene iodonium (DPI) (Fig. 25 
2A). No significant change in ROS levels was observed upon PrSC stimulation with phorbol 12-26 
myristate 13-acetate or ionomycin, which induce NOX1 and NOX5 activity, respectively (not shown). 27 
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This is consistent with their low expression in PrSCs (as before) and indicates that NOX1 and NOX5 1 
do not significantly contribute to the elevated ROS detected during differentiation.  2 
In agreement with tetracycline-inducible NOX4 systems (27), elevated ROS production began 2-6 h 3 
after addition of TGF1. Peak levels were reached at 12 h and remained steady thereafter (Fig. 2C). 4 
Cycloheximide completely abolished TGF1-mediated induction of ROS production indicating de 5 
novo protein synthesis is required (not shown). Elevated ROS production closely correlated with 6 
temporal induction of NOX4 expression, whereas up-regulation of differentiation markers Smooth 7 
Muscle Cell Actin (SMA, ACTG2) and Insulin-like growth factor binding protein 3 (IGFBP3) 8 
occurred later (12-24 h; Fig. 2C), a finding confirmed at the protein level (Fig. 2D). Thus, TGF1-9 
dependent NOX4 induction and elevated intracellular ROS production precede PrSC differentiation. 10 
 11 
Elevated ROS during differentiation do not impose major global DNA damage or protein 12 
oxidation 13 
When cellular ROS scavenging activity is deficient, high ROS levels may induce non-specific damage 14 
to DNA, proteins and lipids via irreversible oxidation, termed oxidative stress (28). We therefore 15 
analyzed the impact of TGF1-induced NOX4 activity on H2A.X levels and the degree of protein 16 
carbonylation as markers of genome-wide DNA damage and oxidation in the cellular proteome, 17 
respectively (29, 30). Whilst there was a marginal increase in H2A.X levels (1.3 fold) during TGF1-18 
mediated differentiation, the degree of DNA damage was significantly lower (p = 0.0002) than in 19 
hydrogen peroxide control treated cells (2.2 fold, p = 0.0006) (Fig. 3A). Moreover, no significant 20 
change in protein carbonylation was detected in TGF1-treated cells relative to bFGF control (Fig. 21 
3B). More specifically, only the reduced (active) form of the readily oxidized PTP family member 22 
PTEN, which migrates slower under non-reducing SDS-PAGE relative to the oxidized (inactive) 23 
phosphatase (31), was present in lysates of PrSCs stimulated for 24 h with bFGF or TGF1 (Fig. 3C). 24 
Furthermore, in PrSCs incubated for 24-72 h with TGF1 there was no significant increase in 25 
phosphorylation of p53 at Ser15, which serves as an early indicator of oxidative-stress induced DNA 26 
damage (32) (Fig. 3D). Thus, despite sustained elevated ROS levels and reduced expression of ROS 27 
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scavenging enzymes, ROS produced in response to TGF1 do not impose major global DNA damage 1 
or protein oxidation. 2 
 3 
Elevated ROS are essential for fibroblast-to-myofibroblast differentiation 4 
ROS produced in response to growth factors and cytokines are emerging as important second 5 
signaling messengers. We therefore investigated whether the elevated ROS produced in response to 6 
TGF1 are required for PrSC differentiation. To this end, the antioxidant enzyme superoxide 7 
dismutase (SOD) conjugated to polyethylene glycol (PEG) to enhance cell permeation was employed. 8 
SOD, which catalyzes the dismutation of superoxide into H2O2 and O2, significantly reduced TGF1-9 
induced ROS levels as determined by luminol-based chemiluminescence (Fig. 4A). Moreover, SOD 10 
inhibited induction of the differentiation markers IGFBP3 and SMA and phenotypic switching (Fig. 11 
4B-C). These data provide key evidence that ROS, most likely superoxide, are essential for TGF1-12 
induced differentiation in PrSCs. 13 
 14 
NOX4 is essential for fibroblast-to-myofibroblast differentiation 15 
To confirm that NOX4 is the ROS-producing source in response to TGF1, NOX4-specific lentiviral-16 
delivered shRNA was employed (Fig. 5A). NOX4 shRNA dose-dependently reduced basal NOX4 17 
expression and significantly attenuated TGF1-induced NOX4 expression (45.9 ±4.7 fold in vector 18 
and scrambled control cells) to just 8.3 ± 2.8 fold (MOI 2; Fig. 5B). Expression of the weakly 19 
detectable NOX1 and NOX5 was not significantly altered (not shown). Due to the limited availability 20 
of NOX4-specific immunological agents (33), it was not possible to verify NOX4 knockdown at the 21 
protein level.  22 
We next investigated whether NOX4 silencing reduced TGF1-induced ROS production. Indeed, 23 
NOX4 knockdown reduced TGF1-induced ROS levels by 64.9% ± 9.1 (Fig. 5C). Residual ROS 24 
levels were most likely due to incomplete silencing of NOX4 since higher levels of NOX4 lentivirus 25 
(MOI 5) further reduced TGF1-induced ROS production (not shown). However, cell viability was 26 
impaired at MOI >6, which is consistent with a threshold basal level of NOX4-derived ROS being 27 
essential for cell survival (34, 35). Subsequent experiments thus employed lentivirus at MOI 2. Under 28 
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these conditions, NOX4 knockdown significantly attenuated TGF1-induction of differentiation 1 
markers IGFBP3 and SMA at the mRNA (-3.7 ± 0.2 and -2.5 ± 0.4 fold, respectively; Fig. 5B) and 2 
protein level (Fig. 5D) compared to vector and scrambled control cells. Basal IGFBP3 and SMA 3 
mRNA and protein levels were not affected by NOX4 knockdown (Fig. 5A and 5D, respectively). The 4 
morphological changes of PrSC fibroblast-to-myofibroblast differentiation (15) were also inhibited 5 
upon NOX4 silencing (not shown). Collectively, these data establish NOX4 as the predominant ROS-6 
producing source induced by TGF1 in PrSCs and an essential mediator of fibroblast-to-myofibroblast 7 
differentiation. 8 
 9 
NOX4 induces JNK phosphorylation to mediate differentiation 10 
The intracellular response to cytokines including TGF1 is transduced by the concerted action of 11 
numerous kinases and phosphatases, whose activity is frequently redox-sensitive (17). We therefore 12 
examined the effect of NOX4 silencing on the phosphorylation status of different kinases during 13 
differentiation. TGF1-induced phosphorylation of PKC and PKB/AKT was not perturbed by NOX4 14 
knockdown and p38 MAPK was not detectably phosphorylated in PrSCs before or after differentiation 15 
(not shown). However, NOX4 silencing reduced TGF1-stimulated but not basal phosphorylation of 16 
JNK (Fig. 5D).  17 
Using a JNK-specific inhibitor (SP600125), we examined the requirement of JNK during 18 
differentiation. Whilst there was no significant change in TGF1-induction of NOX4 mRNA (Fig. 5E), 19 
TGF1-induction of IGFBP3 and SMA and morphological differentiation were inhibited by SP600125 20 
(Fig. 5F and data not shown). Collectively, these data indicate that NOX4 is required for JNK 21 
phosphorylation, which in turn coordinates the downstream differentiation response to TGF. 22 
 23 
Selenium attenuates differentiation by restoring ROS scavenging seleno-enzyme activity 24 
The above data suggest that abrogating NOX4-derived ROS signaling may represent a therapeutic 25 
strategy to inhibit fibroblast-to-myofibroblast differentiation in BPH and PCa, however there are 26 
currently no NOX4-specific inhibitors. We therefore examined whether exogenous Se was sufficient 27 
to restore expression/activity of selenium-containing ROS scavenging enzymes and thereby abrogate 28 
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NOX4-derived ROS signaling to inhibit differentiation. Subcytotoxic concentrations (5 nM) of 1 
selenium as inorganic sodium selenite significantly increased basal expression of TXN and the 2 
selenoenzymes GPX3 and TXNRD1 but not that of non-selenium containing CAT (not shown). 3 
Moreover, differentiation-associated down-regulation of GPX3, TXN and TXNRD1 was completely 4 
inhibited, whereas CAT expression remained comparable to cells treated with TGF1 alone (Fig. 6A). 5 
Despite SEPP1 mRNA levels being unchanged by selenite treatment (Fig. 6A), SEPP1 protein levels 6 
increased upon addition of selenite (Fig. 6B). In addition, TXNRD1 mRNA and protein levels and 7 
enzyme activity were significantly increased upon selenite treatment (TXNRD1 activity 2.0 ± 0.1, p-8 
value 0.004) (Fig. 6B-C). 9 
Consistent with increased selenoenzyme ROS scavenging activity, selenite strongly reduced TGF1-10 
induced ROS levels (9.0 ± 3.8 fold, p-value = 0.01) without significantly attenuating TGF1 induction 11 
of NOX4 mRNA (-2.1 ± 0.3 fold, p-value = 0.07) (Fig. 7A-B). Basal levels of the differentiation 12 
markers IGFBP3 and SMA were unaffected by selenite treatment (Fig. 7C and data not shown). 13 
However, the attenuation of ROS induction by selenite was sufficient to inhibit TGF1-mediated 14 
induction of IGFBP3 and SMA at the mRNA and protein level (Fig. 7B-C). In addition, selenite 15 
reduced pJNK levels as observed upon NOX4 knockdown. Moreover, selenite inhibited phenotypic 16 
switching associated with TGF1-induced differentiation (Fig. 7D). Collectively, these data indicate 17 
that selenite abrogates the initiated TGF1-induced differentiation cascade by restoring the 18 
biosynthesis and activity of ROS scavenging selenoenzymes, thereby depleting NOX4-derived ROS 19 
and attenuating ROS signaling. 20 
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DISCUSSION 1 
Stromal remodeling via fibroblast-to-myofibroblast differentiation promotes the development of BPH 2 
and PCa. Elevated production of TGF1, a potent inducer of fibroblast differentiation in vitro and in 3 
vivo, is considered the inducing stimulus (15, 16, 36, 37). We demonstrate that ROS signaling by 4 
NOX4 induces fibroblast-to-myofibroblast differentiation in PrSCs by increasing phosphorylation of 5 
JNK, which coordinates downstream cytoskeletal remodeling and phenotypic differentiation. NOX4 6 
specifically correlated in vivo with the myofibroblast phenotype, the predominant stromal cell type in 7 
BPH and PCa. Moreover, loss of the Se transporter SEPP1 was observed in the tumor-associated 8 
stroma of PCa biopsies. To our knowledge this is the first report demonstrating dysregulation of redox 9 
homeostasis in stromal remodeling in BPH and PCa. 10 
NOX4 is the major source of elevated ROS during TGF1-mediated PrSC differentiation as 11 
demonstrated by isoform-specific knockdown. The abrogation of differentiation upon depletion of 12 
superoxide by SOD demonstrated the critical role of NOX4-derived ROS as mediators of 13 
differentiation and moreover, suggested that superoxide is the primary ROS signaling mediator rather 14 
than its dismutation product H2O2. 15 
In contrast to many peptide growth factors that induce transient ROS production, PrSCs undergoing 16 
differentiation produce sustained elevated levels of intracellular ROS as demonstrated using the 17 
intracellular redox-sensitive probes DHE and H2DCFDA. Nonetheless, TGF1-differentiated PrSCs 18 
do not exhibit major global DNA damage or protein oxidation, indicating that ROS produced in 19 
response to TGF1 in PrSCs act primarily as intracellular signaling molecules to coordinate 20 
differentiation. In addition to the prostate, TGF1 as well as other peptide growth factors induces 21 
NOX4 expression and ROS production in cells from diverse tissues, including liver, lung, heart and 22 
kidney (20, 21, 38). This suggests that NOX4-derived ROS are a common mediator of TGF/peptide 23 
growth factor signal transduction. 24 
The signaling functions of ROS are primarily mediated by oxidative modification of redox-sensitive 25 
proteins, including transcription factors (e.g. NF-B, AP1, HIF1, p53), protein tyrosine phosphatases 26 
and protein tyrosine kinases (17). Typically, ROS inactivate protein tyrosine phosphatases but activate 27 
protein tyrosine kinases and thereby promote kinase cascades. Consistently, PrSC differentiation was 28 
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associated with NOX4/ROS-dependent phosphorylation of JNK, which was confirmed using 1 
pharmacological inhibition to be essential for transducing the TGF1 differentiation signal 2 
downstream of NOX4. The precise NOX4/ROS target(s) that is responsible for elevated JNK 3 
phosphorylation remain to be identified, however, during differentiation we observed NOX4/ROS-4 
dependent down-regulation of DUSP10, which encodes a dual-specificity phosphatase that selectively 5 
dephosphorylates JNK and p38 (39) (data not shown). These data would be consistent with the 6 
sustained NOX4/ROS-dependent phosphorylation of JNK during differentiation and suggest that 7 
NOX4 modulates pJNK levels, at least in part, by targeting transcription factor(s) that regulate the 8 
expression of DUSP phosphatase(s). 9 
Whilst targeting NOX4-derived ROS signaling directly for therapeutic intervention of PCa/BPH 10 
remains a possibility, there are currently no specific NOX4 inhibitors. We therefore explored the 11 
alternative strategy of increasing ROS scavenging activity. The primary function of SEPP1 is 12 
considered the transport of Se to peripheral tissues, which is required for the expression and 13 
biosynthesis of selenoproteins (23, 24, 40-42). Thus, down-regulation of SEPP1 during differentiation, 14 
a direct transcriptionally suppressed target of TGF1/SMAD (43), may result in cellular Se deficiency, 15 
decreased selenoenzyme ROS scavenging activity and thereby potentiate NOX4-derived ROS 16 
signaling. Indeed, selenite-mediated inhibition of differentiation was associated with (i) reduced 17 
TGF-induced ROS without a reduction in NOX4 mRNA levels, (ii) elevated mRNA levels of the 18 
selenoenzymes GPX3 and TXNRD1 as reported previously (41, 42, 44), (iii) induced TXNRD1 protein 19 
levels and (iv) increased TXNRD1 enzyme activity. Selenite had no effect on SEPP1 mRNA levels, 20 
most likely due to upstream inhibition by TGF1/SMAD (43), however SEPP1 protein levels were 21 
increased presumably via post-translational mechanisms (45). Collectively, these data suggest that 22 
selenite attenuates fibroblast-to-myofibroblast differentiation via enhanced biosynthesis of ROS 23 
scavenging selenoenzymes, which depletes TGF1-induced NOX4-derived ROS thereby preventing 24 
dysregulated NOX4/ROS signaling. 25 
These findings are consistent with a large body of data in experimental animals that Se deficiency or 26 
supplementation increase or reduce tumor incidence, respectively (46-48). However, several large-27 
scale clinical and epidemiological studies yielded conflicting results relating plasma Se levels to the 28 
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risk of PCa and the protective effect of Se supplementation on PCa incidence (49-52). Clearly, further 1 
well-designed studies are required to encompass a number of factors that may have contributed to 2 
these inconsistencies e.g. the source and dose of the Se supplement employed, baseline Se levels, 3 
individual Se requirements and genetic variations within antioxidant and selenoprotein genes (53, 54). 4 
However, together with the data herein the significant reduction in PCa incidence observed in the 5 
Nutritional Prevention of Cancer study suggest that Se supplementation may benefit subpopulations in 6 
whom activity of disease-relevant selenoenzymes are suboptimal, perhaps due to environmental and/or 7 
genetic factors (52, 53). 8 
In summary, NOX4-derived ROS are essential TGF1 signaling effectors that induce the 9 
phosphorylation of JNK. Thereby, downstream transcriptional cascades are activated leading to 10 
prostatic fibroblast-to-myofibroblast differentiation. ROS signaling and differentiation are supported 11 
by the concomitant down-regulation of ROS scavenging selenoenzymes, which can be attenuated by 12 
the addition of Se. To our knowledge, these data are the first to demonstrate dysregulation of redox 13 
homeostasis in pathogenic activation of stromal fibroblasts in age-related proliferative diseases of the 14 
prostate and point to the potential clinical benefit of Se supplementation and/or local NOX4 inhibition 15 
in stromal-targeted therapy. Given that TGF signaling and myofibroblast activation are associated 16 
with numerous fibrotic disorders (e.g. idiopathic lung pulmonary fibrosis, nephrogenic systemic 17 
fibrosis, hypertrophic scarring, proliferative vitreoretinopathies, atherosclerotic lesions) and 18 
tumorigenesis, it will be interesting to see whether similar NOX4-dependent processes are at work. 19 
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MATERIALS AND METHODS 1 
Reagents 2 
Reagents were from Sigma Aldrich unless otherwise specified. Human recombinant TGF1 was from 3 
R&D Systems, kinase inhibitors and concentrations employed were: TGF type 1 receptor activin 4 
receptor-like kinase ALK5 inhibitor SB431542 (1 M, Tocris Bioscience), JNK inhibitor SP600125 (1 5 
M, Calbiochem). Antibodies were obtained as follows: p53, phospho-JNK, TXNRD1 and -tubulin 6 
(Santa Cruz), IGFBP3 and phospho-SMAD2/3 (R&D Systems), -actin and -SMA (Sigma), 7 
phospho-p53, , -H2A.X and PTEN (Cell Signaling), SEPP1 was a kind gift from Holger Steinbrenner 8 
(Düsseldorf, Germany), HRP-conjugated secondary antibodies (Promega). 9 
 10 
Primary cell culture 11 
Human primary prostatic fibroblasts (PrSCs) were established from prostate organoids as described 12 
previously (15).  PrSCs were maintained for routine culture in stromal cell growth medium (SCGM, 13 
Lonza) at 37C in a humidified atmosphere of 5% CO2. For all experiments cells of passage 2-4 were 14 
used directly from culture (not previously frozen). For differentiation, PrSCs were incubated for 12 h 15 
in RPMI 1640 (Lonza) supplemented with 1% charcoal-treated FBS (ctFBS; Hyclone) and antibiotics. 16 
Cells were subsequently stimulated with either 1 ng/ml bFGF as mock control or 1 ng/ml TGF1 for 17 
the indicated duration. For kinase/antioxidant inhibition, cells were pretreated for 1 h with the 18 
appropriate kinase inhibitor/antioxidant or DMSO/PEG equivalent before stimulation with bFGF or 19 
TGF1 as indicated. All experiments were performed at least three times with primary cells from 20 
different donors. 21 
 22 
RNA isolation, cDNA synthesis and qPCR 23 
Prostate samples from the ventral part of the prostate were obtained after radical prostatectomy (n = 24 
13), snap frozen and stored in liquid nitrogen before homogenization and total RNA isolation using 25 
TriZol reagent (Invitrogen). Total RNA from PrSCs was isolated using TriFast reagent (PeqLab). 26 
cDNA synthesis and qPCR were performed as described (15). Primer sequences are given in 27 
Supplementary Table 2. For PrSC experiments cDNA concentrations were normalized by the internal 28 
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standard hydroxymethylbilane synthase (HMBS), a moderate copy number housekeeping gene not 1 
regulated under the experimental conditions employed. Relative changes in gene expression were 2 
calculated as described (55). For prostate samples cDNA concentrations were normalized to HMBS 3 
and EEF1A1. NOX4 expression was compared to the geometric mean expression (ct) value of 4 
epithelial markers (KLK3, KLK2, DPP4, EHF, CDH1, TMPRSS2, CORO2A and KRT5), stromal 5 
markers (SMA, IGF1, TGFB1I1, OGN, CNN1, PAGE4) or myofibroblast markers (COMP, PLN, 6 
RARRES1, COL4A1, TNC). 7 
 8 
Microarrays 9 
PrSCs from three independent donors incubated overnight in 1% ctFBS/RPMI were stimulated either 10 
with 1 ng/ml bFGF as mock control or with 1 ng/ml TGF1 for 48 h. 2 g total RNA from each donor 11 
were pooled and hybridization to Affymetrix Human Genome U133 Plus 2.0 GeneChips® was 12 
performed at the Microarray Facility (Tübingen, Germany). A technical replicate array was performed. 13 
Raw expression data were normalized using the GRCMA algorithm at CARMAweb (56, 57). The 14 
complete microarray dataset is available at ArrayExpress (E-MEXP-2167). 15 
 16 
Lentiviral-mediated knockdown of NOX4 17 
NOX4, scrambled and empty vector shRNA lentiviral particles were generated as described (58). For 18 
viral transduction, PrSCs were seeded in appropriate vessels in SCGM. The following day, media was 19 
replenished supplemented with 8 g/ml polybrene and virus-containing supernatant at the MOI 20 
indicated. After 96 h, cells were incubated overnight in 1% ctBCS supplemented RPMI containing 21 
antibiotics before stimulation with 1 ng/ml TGF1 for the duration indicated. In all experiments, 22 
empty pLKO.1 vector and/or scramble shRNA vector (Addgene plasmid 1864) were used as controls. 23 
 24 
Determination of ROS production 25 
For luminol-based chemiluminescent ROS detection, 20,000 PrSCs in triplicate in 24well plates were 26 
incubated overnight in 1% ctBCS in RPMI before stimulation as indicated. Cell monolayers were 27 
rinsed with pre-warmed Hanks’ Buffered Salt Solution without Ca2+ and Mg2+ (HBSS, Lonza) and 28 
 16
incubated with 4 U/ml horseradish peroxidase and 10 g/ml luminol in HBSS. Luminescence was 1 
measured on a Chameleon luminescence counter (HVD Bioscience) at 37C. Values were normalized 2 
against cell number using the Cell Titer Glo Luminescence assay reagent (Promega). 3 
ROS production was also measured via CM-H2DCFDA in 2 x 105 PrSCs seeded in triplicate in 6 cm 4 
dishes and differentiated as above. Cells were trypsinized, rinsed in pre-warmed HBSS before loading 5 
with 10 M CM-H2DCFDA (Invitrogen) in HBSS for 30 min at 37C. After washing, cells were 6 
resuspended in 500 l HBSS and analyzed by flow cytometry on a FACSCantoTM II (BD Biosciences). 7 
  8 
Western blotting and immunohistochemistry 9 
Isolation of total cell lysates and Western blotting were performed as described (15) and normalized 10 
for total protein content via Bradford assay (Bio-Rad). Detection of protein carbonylation was 11 
performed as described (59). For analysis of PTEN oxidation lysates were prepared in the presence of 12 
10 mM N-ethylmaleimide (NEM) to prevent cysteine oxidation during lysis. Prostate tissue sections 13 
from paraffin blocks of formalin-fixed whole biopsy specimens (obtained from the archives of the 14 
Institute of Pathology at the University Hospital Basel, Switzerland) were processed for 15 
immunohistochemistry as described (60). Where indicated SEPP1 antibody (1:500) was pre-blocked 16 
overnight at 4C in 1% BSA/PBS containing 50g/ml blocking peptide (244-258aa, Alta Bioscience, 17 
UK). 18 
 19 
Analysis of oxidative damage to DNA 20 
5 x 105 PrSCs seeded in triplicate in 10 cm dishes were incubated overnight in 1% ctBCS in RPMI 21 
before stimulation with bFGF or TGF1 for 48 h. Histone H2A.X phosphorylated at Ser139 (H2A.X) 22 
was detected via flow-cytometry on a FACSCantoTM II (BD Biosciences) following immunostaining 23 
according to the manufacturer’s instructions (Cell Signaling). PrSCs treated with non-apoptosis 24 
inducing concentrations of H2O2 (250 M for 60 min) served as positive control. 25 
 26 
TXNRD1 enzyme activity 27 
 17
4.5 x 105 PrSCs seeded in duplicate in 6 cm dishes were differentiated for 48 hrs. Cell monolayers 1 
were rinsed in ice-cold PBS before resuspending in 150l lysis buffer (0.5% Triton X-100, 0.5% 2 
deoxycholate, 150 mM NaCl, 10 mM Tris-HCl pH 7.5, 5 mM EDTA and protease inhibitors). 3 
Samples were incubated on ice for 30 min before centrifugation at 13,000 rpm for 15 min at 4C. 4 
Cleared supernatants were normalized for total protein content via Bradford assay before 5 
determination of TRXND1 activity by a TXNRD1 activity assay kit (Abcam) according to the 6 
manufacturer’s instructions. 7 
 8 
Statistical analysis 9 
Numerical data are presented as mean ±SEM from at least three independent experiments using 10 
independent donors. Statistical evaluation was performed using a Student’s t-test (ns, not significant; 11 
*, p < 0.05; **, p < 0.01). 12 
 18
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FIGURE LEGENDS 1 
Fig. 1. NOX4 and SEPP1 are associated with stromal remodeling in vivo. 2 
(A) qPCR of ROS scavenging (white bars) and ROS producing (black bars) enzymes in PrSCs 3 
differentiated with 1 ng/ml TGF1 (48h) relative to control cells incubated with 1 ng/ml bFGF (48h) 4 
to maintain the fibroblast phenotype. Values represent mean fold change (±SEM) of four independent 5 
experiments using different donors. (B-C) NOX4 expression was evaluated in non-tumor containing 6 
human prostate samples. (B) RTPCR of NOX4 (negative control using water as substrate; positive 7 
control using plasmid DNA containing full-length NOX4 cDNA). RTPCR of HMBS is shown as 8 
loading control. (C) qPCR of NOX4 in prostate specimens (n =13) relative to the expression of 9 
epithelial, stroma or myofibroblast markers as described in Methods. (D) Western blotting of SEPP1 10 
in lysates and supernatants (SN) of PrSCs treated with 1 ng/ml bFGF or TGF1 for 48h. -actin is 11 
shown as loading control. A representative blot of three independent experiments is shown. (E) SEPP1 12 
immunohistochemistry (left) in normal/BPH and PCa biopsies (Gleason 7), enlarged images are 13 
shown (right), pre-incubation of anti-SEPP1 antibody with blocking peptide (center). Periglandular 14 
stromal cells (short black arrows), periglandular tumor stroma (open arrows), SMC bundles (long 15 
black arrow), weak immunostaining of SMCs due to incomplete blocking (grey arrow). Sections were 16 
counterstained with Mayer’s hematoxylin. Tissue specimens were processed in parallel. Images are 17 
representative of four independent experiments with specimens from at least eight different donors. 18 
 19 
Fig. 2. Sustained ROS production precedes fibroblast-to-myofibroblast differentiation.  20 
(A) ROS production was measured real-time in PrSCs 24 h post stimulation with TGF1 or bFGF as 21 
control via luminol-based chemiluminescence. Values represent mean of triplicate wells (±SEM). A 22 
representative example of at least three experiments using independent donors is shown. (B) ROS 23 
production was measured in PrSCs 48 h post stimulation with TGF1or bFGF via H2DCFDA staining 24 
and analyzed by FACS. Values represent mean fluorescence of triplicate samples using three different 25 
donors in independent experiments. Significance is indicated (** p< 0.01). (C) Time course assay of 26 
ROS production (left y-axis) and qPCR (right y-axis) of PrSCs stimulated for the indicated duration 27 
with TGF1. Mean values obtained from at least three experiments using independent donors are 28 
 28
shown (±SEM). (D) Western blotting of lysates from PrSCs stimulated with TGF1 for the indicated 1 
duration with the antibody shown. Blots are representative of three independent experiments using 2 
different donors.  3 
 4 
Fig. 3. Elevated ROS production during differentiation do not induce major global DNA 5 
damage or protein oxidation.  6 
(A) H2A.X phosphorylated at Ser139 was quantified via flow-cytometry in PrSCs stimulated for 48 h 7 
with either bFGF or TGF1. Top panel, histograms from a single experiment of H2A.X staining 8 
intensity in PrSCs treated as indicated (negative control, omission of primary antibody in bFGF treated 9 
samples). Note the increased (right-ward) shift in staining intensity in H2O2 relative to bFGF and 10 
TGF1-treated samples. Lower panel, mean values (±SEM) of triplicate samples using different 11 
donors in three independent experiments. (B, top panel) PrSCs were treated for the indicated duration 12 
with either bFGF or TGF1 before detection of total protein carbonyl levels via immunoblotting for 13 
anti-DNP immunoreactive proteins in cell extracts derivatized with DNPH (negative control, non-14 
derivatized cell lysate from H2O2 treated PrSCs). Lower panel, densitometric quantification of total 15 
protein carbonyl levels in PrSCs treated as before. Mean values (±SEM) of three independent 16 
experiments using different donors are shown. Significance is indicated (**, p< 0.01; ns, not 17 
significant). (C, D) Western blotting of lysates from PrSCs stimulated with bFGF or TGF1 for the 18 
indicated duration (C, 24 h; D, hours) with the antibody shown. Blots are representative of three 19 
independent experiments using different donors. (A-D) As positive control, PrSCs were incubated 20 
with bFGF for 24 (B-D) or 48 h (A) before subsequent treatment with 250 M H2O2 for 60 min. 21 
 22 
Fig. 4. ROS are essential for fibroblast-to-myofibroblast differentiation 23 
PrSCs were incubated with polyethylene glycol (PEG)-conjugated superoxide dismutase (PEG-SOD, 24 
60 U/ml) and bFGF or TGF1 as indicated for 24 h prior to (A) luminol-based chemiluminescent 25 
detection of ROS production, (B) Western blotting using the indicated antibodies or (C) phase contrast 26 
microscopy (magnification x 40). (A) Values represent the mean (±SEM) of triplicate wells in three 27 
independent experiments using different donors. Significance is indicated (*, p< 0.05; **, p< 0.01; ns, 28 
 29
not significant). (C) Note the thin, elongated and light refractive phenotype of bFGF-treated PrSCs 1 
(fibroblasts) in comparison to the flattened and less light refractive morphology of TGF1-2 
differentiated PrSCs (myofibroblasts). (B, C) Images are representative of at least four independent 3 
experiments using different donors. 4 
 5 
Fig. 5. NOX4-derived ROS mediate differentiation via increased JNK phosphorylation. 6 
(A) qPCR of PrSCs infected with the indicated shRNA-expressing lentivirus at MOI 2 (vector and 7 
scrambled) or the indicated MOI (NOX4) for 96 h. (B) qPCR of PrSCs infected as above (MOI 2) and 8 
subsequently stimulated for 24 h with TGF1. (A, B) Mean values (±SEM) of at least three 9 
experiments using independent donors are shown relative to non-transduced mock treated PrSCs. (C) 10 
luminol-based chemiluminescent detection of ROS production by PrSCs treated as in (B). Values 11 
represent mean fold change in ROS production (±SEM) from triplicate wells in at least three 12 
experiments using independent donors relative to vector control cells. (D) Western blotting of total 13 
cell lysates from PrSCs treated as in (B) in the presence or absence of TGF1 for 24 h. A 14 
representative example of four independent experiments using different donors is shown. Values 15 
denote densitometric quantification of bands from NOX4 shRNA treated lysates relative to combined 16 
scores from vector and scrambled shRNA treated lysates (mean ±SEM). (E-F) PrSCs were treated 17 
with TGF1 and the indicated inhibitor (JNK, 1 M SP600125; ALK5/TGFR1, 1 M SB431542) for 18 
24 h before (E) qPCR of the indicated genes or (B) Western blotting of total cell lysates using the 19 
antibodies indicated. (E) Mean values from at least three independent experiments using different 20 
donors are shown expressed as percentage (±SEM) relative to mock control treated with TGF1 and 21 
DMSO equivalent. (F) A representative example of three independent experiments using different 22 
donors is shown. Significance is indicated (* p< 0.05, ** p< 0.01). 23 
 24 
Fig. 6. Selenite restores expression and activity of ROS scavenging selenoenzymes. 25 
(A) qPCR of the indicated genes in PrSCs pre-treated for 12 h with 5 nM sodium selenite or mock 26 
control in 1% ctBCS/RPMI before stimulation with TGF1 for a further 24 h. Values represent mean 27 
fold change in gene expression (±SEM) relative to bFGF control (without selenite). (B) Western 28 
 30
blotting of total cell lysates from cells pre-incubated with selenite as in (A) and subsequently 1 
stimulated either with bFGF or TGF1 as indicated in the presence or absence of selenite for a further 2 
24 h. Blots are representative of three independent experiments using different donors. (C) Mean fold 3 
change in TXNRD1 enzyme activity (±SEM) in cell extracts from PrSCs treated with 5 nM selenite 4 
relative to mock treated controls. (A-C) Data are derived from at least three independent experiments 5 
using different donors. Significance is indicated (** p< 0.01, * p< 0.05). 6 
 7 
Fig. 7. Selenite inhibits TGF1-mediated fibroblast-to-myofibroblast differentiation. 8 
PrSCs were pre-treated for 12 h with 5 nM sodium selenite or mock control before stimulation with 1 9 
ng/ml bFGF or TGF1 in the presence or absence of selenite for a further 24 h. Cells were 10 
subsequently processed for (A) ROS determination via luminol-based chemilumiscence, (B) qPCR of 11 
the indicated genes, (C) Western blotting of total cell lysates using the antibodies indicated or (D) 12 
phase contrast microscopy (magnification x40). Note the thin, elongated and light refractive 13 
phenotype of bFGF-treated PrSCs (fibroblasts) in comparison to the flattened and less light refractive 14 
morphology of TGF1-differentiated PrSCs (myofibroblasts). (C, D) Images are representative of at 15 
least four independent experiments using different donors. (A, B) Values represent mean fold change 16 
(±SEM) relative to bFGF control (without selenite) from four independent experiments using different 17 
donors. Significance is indicated (** p< 0.01, * p< 0.05, ns not significant). 18 
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 Description Gene symbol 
Mean 
fold 
changea 
SEM 
        
Extracellular matrix component, tissue remodeling         
ADAM metallopeptidase with thrombospondin type 1 
motif, 1 ADAMTS1 -22.50 8.39         
ADAM metallopeptidase with thrombospondin type 1 
motif, 19 ADAMTS19 -5.32 2.10         
ADAM metallopeptidase with thrombospondin type 1 
motif, 2 ADAMTS2 4.31 0.67         
ADAM metallopeptidase with thrombospondin type 1 
motif, 5  ADAMTS5 -4.29 1.15         
ADAM metallopeptidase with thrombospondin type 1 
motif, 6 ADAMTS6 9.15 1.00         
biglycan BGN 8.73 0.02         
cadherin 2, type 1, N-cadherin  CDH2 7.29 0.75         
cartilage oligomeric matrix protein COMP 180.49 17.16         
chondroitin sulfate proteoglycan 2 (versican) CSPG2 6.46 2.03         
collagen, type IV, alpha 1 COL4A1 21.06 1.29         
collagen, type IV, alpha 2 COL4A2 9.51 0.48         
collagen, type V, alpha 1 COL5A1 7.07 0.43         
decorin DCN -5.24 1.41         
desmoplakin DSP 24.54 15.15         
integrin, alpha 11 ITGA11 10.52 2.35         
integrin, beta-like 1 (with EGF-like repeat domains) ITGBL1 6.15 1.22         
lysyl oxidase LOX 3.94 0.52         
lysyl oxidase-like 2 LOXL2 4.25 1.10         
matrix Gla protein MGP 11.17 3.35         
membrane metallo-endopeptidase MME -7.10 0.54         
microfibrillar-associated protein 2 MFAP2 17.19 3.92         
neurofilament, light polypeptide 68kDa NEFL -15.00 1.86         
pappalysin 2 PAPPA2 3.03 0.76         
plasminogen activator, tissue PLAT -6.97 2.23         
prostaglandin E synthase PTGES -21.49 1.02         
sarcoglycan, gamma  SGCG 3.08 0.72         
serpin peptidase inhibitor, clade B (ovalbumin), member 1 SERPINB1 -7.92 2.31         
serpin peptidase inhibitor, clade E  member 2 SERPINE2 19.65 8.79         
serpin peptidase inhibitor, clade E member 1 SERPINE1 5.46 0.03         
thrombospondin 1 THBS1 6.64 0.12         
TIMP metallopeptidase inhibitor 3 TIMP3 7.16 1.77         
Smooth muscle cell/myofibroblast markers         
actin, alpha 2, smooth muscle ACTA2 13.32 4.23         
caldesmon 1 CALD1 8.06 4.69         
calponin 1, basic, smooth muscle CNN1 12.99 1.71         
phospholamban PLN 344.95 89.14         
tenascin TNC 24.45 6.77         
Growth factors         
connective tissue growth factor CTGF 3.42 0.08         
epidermal growth factor EGF 14.08 4.54         
fibroblast growth factor 1 FGF1 9.43 0.90         
fibroblast growth factor 18 FGF18 7.86 0.52         
heparin-binding EGF-like growth factor HBEGF 68.54 3.27         
 pleiotrophin (heparin binding growth factor 8) PTN -3.29 0.67         
Insulin-like growth factor axis         
insulin-like growth factor 1 IGF1 24.83 6.88         
insulin-like growth factor 1 receptor IGF1R 3.11 0.72         
insulin-like growth factor binding protein 3 IGFBP3 9.53 2.75         
insulin-like growth factor binding protein 5 IGFBP5 -6.78 0.69         
insulin-like growth factor binding protein 7 IGFBP7 6.31 0.31         
NUAK family, SNF1-like kinase, 1 NUAK1 9.43 1.04         
Wilms tumor 1 WT1 -9.02 4.79         
Transforming growth factor beta 1 axis         
cyclin-dependent kinase inhibitor 2B (p15) CDKN2B 20.68 1.66         
inhibin, beta E INHBE 15.86 3.18         
transforming growth factor, beta 1 TGFB1 5.31 2.07         
transmembrane, prostate androgen induced RNA TMEPAI 191.92 10.25         
ROS production/scavenging         
catalase CAT -3.37 0.11         
glutathione peroxidase 3 GPX3 -3.39 0.12         
NAD(P)H dehydrogenase, quinone 1 NQO1 -5.57 0.59         
NADPH oxidase 4 NOX4 436.57 20.75         
neutrophil cytosolic factor 2  (p67phox) NCF2 11.80 4.67         
selenoprotein P 1 SEPP1 -7.18 0.16         
superoxide dismutase 2, mitochondrial SOD2 -7.11 0.00         
thioredoxin reductase 1 TXNRD1 -3.99 0.20         
Immune response         
collectin sub-family member 12 COLEC12 -56.56 21.61         
complement component 3 C3 -15.70 9.15         
interleukin 11 IL11 36.08 0.49         
tumor necrosis factor superfamily, member 4  TNFSF4 7.38 0.22         
Signal transduction/transcription factor         
cytokine receptor-like factor 1 CRLF1 35.24 3.51         
early growth response 2 EGR2 72.83 16.67         
EPH receptor A7 EPHA7 -17.85 10.76         
neuronal PAS domain protein 3 NPAS3 -4.48 1.58         
oxytocin receptor OXTR 3.94 0.56         
phosphodiesterase 1A, calmodulin-dependent PDE1A -6.49 1.76         
Phosphodiesterase 5A, cGMP-specific PDE5A -8.59 1.60         
plexin domain containing 2 PLXDC2 13.01 4.39         
prostaglandin-endoperoxide synthase 1 (COX1) PTGS1 5.36 1.35         
RAB27B, member RAS oncogene family RAB27B -80.64 10.02         
regulator of G-protein signalling 4 RGS4 5.55 0.04         
runt-related transcription factor 1 RUNX1 7.92 2.30         
secreted frizzled-related protein 1 SFRP1 -5.83 0.26         
serologically defined colon cancer antigen 33 SDCCAG33 9.61 0.42         
tetraspanin 13 TSPAN13 16.13 2.22         
tetraspanin 2 TSPAN2 120.84 0.98         
Transport         
aquaporin 1 AQP1 83.85 37.05         
potassium inwardly-rectifying channel, subfamily J, 
member 2 KCNJ2 -28.42 10.56         
solute carrier family 39 (zinc transporter), member 8 SLC39A8 -3.42 0.21         
Miscellaneous/unknown         
   LOC541469 10.58 1.54         
  FLJ37228 -12.85 0.48         
alcohol dehydrogenase IB (class I), beta polypeptide ADH1B -13.26 5.91         
ankyrin repeat domain 37 ANKRD37 7.19 2.34         
carbonic anhydrase XII CA12 -13.55 3.51         
chromosome 10 open reading frame 116 C10orf116 -5.43 0.64         
chromosome 5 open reading frame 13 C5orf13 4.31 2.23         
hect domain and RLD 6 HERC6 -5.64 0.38         
hydroxysteroid (11-beta) dehydrogenase 1 HSD11B1 -8.44 2.91         
interferon-induced protein with tetratricopeptide repeats 3 IFIT3 -8.97 0.28         
suppression of tumorigenicity 7 like ST7L -13.09 6.28         
transmembrane protein with EGF-like and two follistatin-
like domains 2 TMEFF2 -11.06 3.65         
X-ray repair complementing defective repair in Chinese 
hamster cells 4 XRCC4 17.11 2.26         
 
PrSCs from three independent donors were treated with 1 ng/ml TGFβ1 or 1 ng/ml bFGF for 48 
h. Pooled RNA was hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChips®. 
a Values represent mean fold change in expression relative to bFGF control cells from two 
independent hybridizations         
 
 
Supplementary Table 1 Most highly regulated genes during TGFβ1-mediated 
transdifferentiation of primary human prostatic stromal cells. 
 Gene 
Symbol 
Gene 
ID Primer sequence
a 
ACTG2 (SMA) 72 F: AGAAGAGCTATGAGCTGCCA R: GCTGTGATCTCCTTCTGCAT 
CAT 847 F: CGTGCTGAATGAGGAACAGA R: CAGATTTGCCTTCTCCCTTG 
CDH1 999 F: ATTGCAAATTCCTGCCATTC R: GCTGGCTCAAGTCAAAGTCC 
CNN1 1264 F: GGTGAACGTGGGAGTGAAGT R: GGTCCAGAGGCTGGTCTGT 
COL4A1 1282 F: CCGGATTGAAAGGAGATCAA R: GCCTGGATCTTCTCACCTTG 
COMP 1311 F: GGAGATCACGTTCCTGAAAA R: GGTGTTGATACAGCGGACTC 
CORO2A 7464 F: GAGCCCATCTCCATGATTGT R: GGGCCATGGAATTGAAGATA  
CYBA (p22phox) 1535 F: GTCCTGCATCTCCTGCTCT R: ACAGCCGCCAGTAGGTAGA 
DPP4 1803 F: CGTTACATGGGTCTCCCAAC R: CAGGGCTTTGGAGATCTGAG 
DUSP1 1842 F: CTGCCTTGATCAACGTCTCA R: ACCCTTCCTCCAGCATTCTT 
DUSP2 1844 F: GTGGAGATCAGTGCCTGGTT R: ACAGCACCTGGGTCTCAAAC 
DUSP6 1848 F: CCTGGAAGGTGGCTTCAGTA R: GTTGGACAGCGGACTACCAT 
DUSP10 11221 F: TGAATGTGCGAGTCCATAGC R: GTTGCAGAGCCAAGGTAAC 
EHF 26298 F: AACCCGAGAGGGACTCACTT R: ACCAGTCTTCGTCCATCCAC 
GPX3 2878 F: CCCTCAAGTATGTCCGACCA R: CAGAAGAGGCGGTCAGATGT 
HMBS 3145 F: CCAGGACATCTTGGATCTGG R: ATGGTAGCCTGCATGGTCTC 
IGF1 3479 F: GGAGGCTGGAGATGTATTGC R: GATGTGTCTTTGGCCAACCT 
IGFBP3 3486 F: CAAGCGGGAGACAGAATATG R: TTATCCACACACCAGCAGAA 
KLK2 3817 F: GTGGACACCTGTGTCAGCAT R: TGTGCCCATCCATGACTGTA 
KLK3 (PSA) 354 F: TTGACCCCAAAGAAACTTCA R: TGACGTGATACCTTGAGGCA 
KRT5 3852 F: AGGAGCTCATGAACACCAAG R: CCAGAGGAAACACTGCTTGT 
NCF2 (p67phox) 4688 F: GAGAACACAGTGGGTGACCA R: AGGTCCTCTGGTTGGGTAG 
NOX1 27035 F:TGGTCATGCAGCATTAAACTTTG R: CATTGTCCCACATTGGTCTCC 
NOX4 50507 F: TGGCAAGAGAACAGACCTGA R: TGGGTCCACAACAGAAAACA 
NOX5 79400 F: CCCTTTGCTTCCATTCTG R: TCACAAACCACTCGAAAGA 
OGN 4969 F: GCCTCTGATAAAGCCAGCAC R: ACGTGGGCATTTCATCATTT 
PAGE4 9506 F: AATGGATCTGAAAAAGACTCG R: GTGACATCAGCCATGTGTGTA 
PLN 5350 F: ACAGCTGCCAAGGCTACCTA R: GCTTTTGACGTGCTTGTTGA 
PTP1B (PTPN1) 5770 F: GAATCCTGGAGCCACACAAT R: TTGACTCATGCTTTCGATGC 
RARRES1 5918 F: TCATCTGGGATTTGGCTTTC 
  
 
 
 
 
 
 
 
 
 
Supplemental Table 2 Primer sequences 
RARRES1 5918 F: TCATCTGGGATTTGGCTTTC 
R: CCAGGGTACCAGACCAAGTG 
SEPP1 6414 F: TGGAAACTGCTCTCTCACGA R: GCTCCTGGTTGCTGATTCTC 
SOD2 6648 F: TCCACTGCAAGGAACAACAG R: TCTTGCTGGGATCATTAGGG 
TGFB1I1 7041 F: GCTTCAGGAACTTAATGCCA R: GAAGTCAGAGAGTGAGGCCA 
TMPRSS2 7113 F: GGCTTTGAACTCAGGGTCAC R: GGTAGTACTGAGCCGGATGC 
TNC 3371 F: GGAAACAAGAGCAGGACCAG R: CAGACAGCCAATGCTTCAGA 
TXN 7295 F: CTGCTTTTCAGGAAGCCTTG R: ACCCACCTTTTGTCCCTTCT 
a Primer sequences are given 5’ to 3’, annealing temperature for all 
primers in qPCR is 56°C, all primers span at least one intron 
